摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+)-spongistatin 1 | 149715-96-8

中文名称
——
中文别名
——
英文名称
(+)-spongistatin 1
英文别名
(+)-spongistatin;spongistatin 1;altohyrtin A;spongistatin;Spongistatin-1;[(1S,3S,5R,9R,10R,11R,13R,14S,15R,17S,18R,19R,23Z,25R,27S,29S,31S,33S,36S,37S,38R,41S,43S,49S)-37-acetyloxy-11-[(4S,5E)-7-chloro-4-hydroxy-2-methylideneocta-5,7-dienyl]-10,14,15,17,27,43-hexahydroxy-31-methoxy-18,36,38,43,49-pentamethyl-39-methylidene-7,35-dioxo-8,12,45,46,47,48,50-heptaoxaheptacyclo[39.3.1.11,5.19,13.115,19.125,29.129,33]pentacont-23-en-3-yl] acetate
(+)-spongistatin 1化学式
CAS
149715-96-8
化学式
C63H95ClO21
mdl
——
分子量
1223.89
InChiKey
ICXJVZHDZFXYQC-XKQUEHJYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    1186.6±65.0 °C(Predicted)
  • 密度:
    1.30±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    85
  • 可旋转键数:
    11
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.78
  • 拓扑面积:
    302
  • 氢给体数:
    7
  • 氢受体数:
    21

SDS

SDS:60a6d18a5636ff3d8f4c65cd9602837c
查看

反应信息

  • 作为反应物:
    参考文献:
    名称:
    冲绳海豚海绵体Altohyrtin A及其同类物的绝对立体结构,有效的细胞毒性大环内酯类化合物
    摘要:
    altohyrtins A(绝对立体结构1),B(2),C(3),和5- desacetylaltohyrtin A(4),其是从冲绳海绵分离Hyrtios altum,已经阐明。
    DOI:
    10.1016/0040-4039(94)88034-4
  • 作为产物:
    描述:
    [(1S,3S,5R,9R,10R,11R,13R,14S,15R,17S,18S,19R,23Z,25R,27S,29R,31S,33S,36S,37S,38R,41S,43S,49S)-37-acetyloxy-17,27-bis[[tert-butyl(dimethyl)silyl]oxy]-11-[(4S,5E)-4-[tert-butyl(dimethyl)silyl]oxy-7-chloro-2-methylideneocta-5,7-dienyl]-10-hydroxy-15,31-dimethoxy-18,36,38,43,49-pentamethyl-39-methylidene-7,35-dioxo-14,43-bis(triethylsilyloxy)-8,12,45,46,47,48,50-heptaoxaheptacyclo[39.3.1.11,5.19,13.115,19.125,29.129,33]pentacont-23-en-3-yl] acetate 在 氢氟酸 作用下, 以 乙腈 为溶剂, 反应 20.0h, 以87%的产率得到(+)-spongistatin 1
    参考文献:
    名称:
    海绵吡喃合成研究。(+)-海绵抑素 1 的可扩展全合成的演变
    摘要:
    报道了结构复杂、细胞毒性海洋大环内酯 (+)-海绵抑素 1 ( 1 ) 的三种合成。第一代合成的亮点包括:使用二噻烷多组分关键偶联策略构建 AB 和 CD 螺缩酮,并通过高选择性埃文斯硼介导的醇醛反应生成 ABCD 醛;通过路易斯酸介导的葡萄糖环氧化物与烯丙基锡烷的开环引入C(44)–C(51)侧链以组装EF亚基;最终片段通过 ABCD 和 EF 亚基的 Wittig 偶联形成 C(28)–C(29) 烯烃,然后进行区域选择性 Yamaguchi 大内酯化和全局脱保护。第二代和第三代合成的目的是获得 1 g (+)-海绵抑素 1 ( 1 ),保留了第一代 ABCD 醛和最终片段结合的策略,同时结合了两种更有效的方法用于构建 EF Wittig 盐。后者将 E 环和 F 环原体的原始螯合控制二噻烷结合与高效氰醇烷基化的应用相结合以附加 F 环侧链,并结合两种独立的策略来访问 F 环吡喃。第一个
    DOI:
    10.1016/j.tet.2009.04.003
点击查看最新优质反应信息

文献信息

  • The stereocontrolled total synthesis of altohyrtin A/spongistatin 1: fragment couplings, completion of the synthesis, analogue generation and biological evaluation
    作者:Ian Paterson、David Y.-K. Chen、Mark J. Coster、José L. Aceña、Jordi Bach、Debra J. Wallace
    DOI:10.1039/b504151a
    日期:——
    The antimitotic marine macrolide altohyrtin A/spongistatin 1 has been synthesised in a highly convergent and stereocontrolled manner, thus contributing to the replenishment of the largely exhausted material from the initial isolation work. Coupling of the AB- and CD-spiroacetal subunits by a stereoselective aldol reaction was achieved by using either a lithium (67 : 33 dr) or boron enolate (90 : 10
    抗有丝分裂海洋大环内酯altohyrtin A /海绵抑素1以高度会聚和立体控制的方式合成,因此有助于从最初的分离工作中补充大量消耗的物质。通过使用锂(67:33 dr)或烯醇硼(90:10 dr),通过立体选择性醛醇缩合反应将AB-和CD-螺缩醛亚基偶联。高度(Z)选择性的Wittig偶联用于将北半球醛与南半球salt盐结合在一起。在三醇癸二酸上进行脱保护并随后进行区域选择性大环内酯化,完成了altohyrtin A的合成。还制备了两种结构类似物,并评估了它们作为针对一系列人类肿瘤细胞系(包括紫杉醇抗性菌株)的生长抑制剂,
  • Stereocontrolled Total Synthesis of (+)-Altohyrtin A/Spongistatin 1 Financial support was provided by the EPSRC (GR/L41646), Cambridge Commonwealth Trust (Scholarship to M.J.C.), EC (Marie Curie Postdoctoral Fellowship to J.L.A.), DFG (Postdoctoral Fellowship to T.T.), NSERC-Canada (Postdoctoral Fellowship to R.M.O.), Churchill College (Research Fellowship to D.J.W.), Kingapos;s College and Sims Fund, Cambridge (Scholarship to D.Y.K.C.). We also thank Merck and AstraZeneca Pharmaceuticals for generous support, and Dr. Anne Butlin (AZ) and Dr. Nick Bampos (Cambridge) for valuable assistance.
    作者:Ian Paterson、David Y.-K. Chen、Mark J. Coster、Jose L. Aceña、Jordi Bach、Karl R. Gibson、Linda E. Keown、Renata M. Oballa、Thomas Trieselmann、Debra J. Wallace、Andrew P. Hodgson、Roger D. Norcross
    DOI:10.1002/1521-3773(20011105)40:21<4055::aid-anie4055>3.0.co;2-h
    日期:2001.11.5
    antimitotic macrolide, altohyrtin A/spongistatin 1 shows great promise in cancer chemotherapy but its extreme scarcity in the natural sponges has halted its further preclinical development. A highly stereocontrolled total synthesis, which exploits boron-mediated aldol bond constructions, has been realized to provide, for the first time, a useful amount of synthetic material.
    作为一种异常有效的抗有丝分裂大环内酯,altohyrtin A / spongistatin 1在癌症化学疗法中显示出广阔的前景,但其天然海绵中的极度稀缺性阻止了其进一步的临床前开发。已经实现了利用硼介导的羟醛键结构的高度立体控制的全合成,首次提供了有用量的合成材料。
  • [EN] PRODRUGS OF HYDROXYL-COMPRISING DRUGS<br/>[FR] PROMÉDICAMENTS DE MÉDICAMENTS COMPRENANT DES GROUPES HYDROXYLE
    申请人:ASCENDIS PHARMA AS
    公开号:WO2013160340A1
    公开(公告)日:2013-10-31
    The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a biologically active moiety-linker conjugate D-L, wherein D is a hydroxyl-comprising biologically active moiety; and L is a promoiety comprising a moiety L1 represented by formula (I) and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer and Z is a carrier group. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.
    本发明涉及一种前药或其药学上可接受的盐,包括生物活性基团-连接物D-L的共轭物,其中D是含有羟基的生物活性基团;L是包含由式(I)表示的基团L1的前基团,其中L1被一个到四个基团L2-Z取代,并且可选择进一步取代,前提是式(I)中带星号标记的氢未被取代;其中L2是一个化学键或一个间隔物,Z是一个载体基团。该发明还涉及包含所述前药的药物组合物及其作为药物的用途。
  • Gram-Scale Synthesis of (+)-Spongistatin 1: Development of An Improved, Scalable Synthesis of the F-Ring Subunit, Fragment Union, and Final Elaboration
    作者:Amos B. Smith、Takashi Tomioka、Christina A. Risatti、Jeffrey B. Sperry、Chris Sfouggatakis
    DOI:10.1021/ol801792k
    日期:2008.10.2
    In a quest to develop an effective, scalable synthesis of (+)-spongistatin 1 ( 1), we devised a concise, third-generation scalable synthesis of (+)- 7, the requisite F-ring tetrahydropyran aldehyde, employing a proline-catalyzed cross-aldol reaction. Subsequent elaboration to (+)-EF Wittig salt (+)- 3, followed by union with advanced ABCD aldehyde (-)- 4, macrolactonization and global deprotection
    为了开发一种有效、可规模化的 (+)-海绵抑素 1 (1) 合成方法,我们设计了一种简洁的第三代可规模化合成 (+)- 7,这是必需的 F 环四氢吡喃醛,采用脯氨酸-催化交叉羟醛反应。随后精制为 (+)-EF Wittig 盐 (+)- 3,然后与先进的 ABCD 醛 (-)- 4 结合、大环内酯化和整体脱保护,从而获得 >1.0 g 的全合成 (+)-海绵抑素 1 ( 1 )。
  • Total Synthesis of (+)-Spongistatin 1. An Effective Second-Generation Construction of an Advanced EF Wittig Salt, Fragment Union, and Final Elaboration
    作者:Amos B. Smith、Wenyu Zhu、Shohei Shirakami、Chris Sfouggatakis、Victoria A. Doughty、Clay S. Bennett、Yasuharu Sakamoto
    DOI:10.1021/ol034037a
    日期:2003.3.1
    A stereocontrolled, total synthesis of (+)-spongistatin 1 (1) has been achieved. Union of a second-generation EF Wittig salt (+)-3 with the advanced ABCD aldehyde (-)-4, followed by regioselective macrolactonization and global deprotection afforded (+)-spongistatin 1 (1). The longest linear sequence, 29 steps, proceeded in 0.5% overall yield.
    实现了立体控制的(+)-海绵抑素1(1)的全合成。将第二代EF维蒂希盐(+)-3与先进的ABCD醛(-)-4结合,然后进行区域选择性大环内酯化和整体脱保护,得到(+)-海绵抑素1(1)。最长的线性序列(29步)以0.5%的总产率进行。
查看更多